# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Barclays analyst Luke Sergott maintains 10x Genomics (NASDAQ:TXG) with a Overweight and lowers the price target from $36 to ...
Wolfe Research analyst Doug Schenkel downgrades 10x Genomics (NASDAQ:TXG) from Outperform to Peer Perform.
On Wednesday, Cathie Wood-led Ark Invest made significant trades in Roku Inc (NASDAQ:ROKU) and Coinbase Global Inc (NASDAQ:COIN...
Guggenheim analyst Subbu Nambi downgrades 10x Genomics (NASDAQ:TXG) from Buy to Neutral.
Guggenheim analyst Subbu Nambi downgrades 10x Genomics (NASDAQ:TXG) from Buy to Neutral.